Core Insights - Watson Bio has received approval from the National Medical Products Administration for a clinical trial of its mRNA vaccine targeting respiratory syncytial virus (RSV) [1][2] Group 1: Clinical Trial Approval - The clinical trial approval notification for the RSV mRNA vaccine was issued with the registration numbers 2025LP02790 and 2025LP02791 [1] - The vaccine is classified as a preventive biological product and aims to prevent lower respiratory tract diseases caused by RSV infection [1] Group 2: Vaccine Development - The vaccine is developed through a collaboration between Watson Bio, Fudan University, and Blue Magpie Biopharmaceuticals, utilizing a self-established mRNA vaccine technology platform [2] - The vaccine design is based on a highly conserved sequence of the RSV-A strain F protein, incorporating various mutations for optimized antigen expression [2]